# Universal Health Services Inc: financial statements, quarterly UHS · NYSE · CIK 352915 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31 Pages: [Overview](/companies/uhs.md) · [Financials](/companies/uhs/financials.md) · [Filings](/companies/uhs/filings.md) · [Insiders](/companies/uhs/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/uhs/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [3,563](/filings/0000950170-24-124103.md) | [3,704 d](/filings/0001193125-26-071676.md) | [3,844](/filings/0000950170-25-067010.md) | [3,908](/filings/0000950170-25-105857.md) | [3,963](/filings/0001193125-25-272385.md) | [4,114 d](/filings/0001193125-26-071676.md) | [4,100](/filings/0001193125-26-211992.md) | [4,284](/filings/0001193125-26-340278.md) | [4,495](/filings/0001193125-25-272385.md) | [4,486 d](/filings/0001193125-26-071676.md) | [4,495](/filings/0001193125-26-211992.md) | [4,638](/filings/0001193125-26-340278.md) | | Operating income | $m | [285](/filings/0000950170-24-124103.md) | [331 d](/filings/0001193125-26-071676.md) | [389](/filings/0000950170-25-067010.md) | [436](/filings/0000950170-25-105857.md) | [384](/filings/0001193125-25-272385.md) | [472 d](/filings/0001193125-26-071676.md) | [455](/filings/0001193125-26-211992.md) | [500](/filings/0001193125-26-340278.md) | [522](/filings/0001193125-25-272385.md) | [517 d](/filings/0001193125-26-071676.md) | [503](/filings/0001193125-26-211992.md) | [517](/filings/0001193125-26-340278.md) | | Interest expense | $m | [53.4](/filings/0000950170-24-124103.md) | [53.6 d](/filings/0001193125-26-071676.md) | [52.8](/filings/0000950170-25-067010.md) | [48.9](/filings/0000950170-25-105857.md) | [44.7](/filings/0001193125-25-272385.md) | [39.7 d](/filings/0001193125-26-071676.md) | [40.1](/filings/0001193125-26-211992.md) | [35.4](/filings/0001193125-26-340278.md) | [38.4](/filings/0001193125-25-272385.md) | [42.2 d](/filings/0001193125-26-071676.md) | [37.1](/filings/0001193125-26-211992.md) | [39.9](/filings/0001193125-26-340278.md) | | Income tax | $m | [52.5](/filings/0000950170-24-124103.md) | [61.5 d](/filings/0001193125-26-071676.md) | [70.3](/filings/0000950170-25-067010.md) | [87.7](/filings/0000950170-25-105857.md) | [75.6](/filings/0001193125-25-272385.md) | [101 d](/filings/0001193125-26-071676.md) | [98.8](/filings/0001193125-26-211992.md) | [111](/filings/0001193125-26-340278.md) | [118](/filings/0001193125-25-272385.md) | [134 d](/filings/0001193125-26-071676.md) | [110](/filings/0001193125-26-211992.md) | [115](/filings/0001193125-26-340278.md) | | Net income | $m | [167](/filings/0000950170-24-124103.md) | [216 d](/filings/0001193125-26-071676.md) | [262](/filings/0000950170-25-067010.md) | [289](/filings/0000950170-25-105857.md) | [259](/filings/0001193125-25-272385.md) | [332 d](/filings/0001193125-26-071676.md) | [317](/filings/0001193125-26-211992.md) | [353](/filings/0001193125-26-340278.md) | [373](/filings/0001193125-25-272385.md) | [446 d](/filings/0001193125-26-071676.md) | [349](/filings/0001193125-26-211992.md) | [358](/filings/0001193125-26-340278.md) | | Diluted EPS | $ per share | [2.40](/filings/0000950170-24-124103.md) | not reported | [3.82](/filings/0000950170-25-067010.md) | [4.26](/filings/0000950170-25-105857.md) | [3.80](/filings/0001193125-25-272385.md) | not reported | [4.80](/filings/0001193125-26-211992.md) | [5.43](/filings/0001193125-26-340278.md) | [5.86](/filings/0001193125-25-272385.md) | not reported | [5.65](/filings/0001193125-26-211992.md) | [5.98](/filings/0001193125-26-340278.md) | | Basic EPS | $ per share | [2.42](/filings/0000950170-24-124103.md) | not reported | [3.90](/filings/0000950170-25-067010.md) | [4.32](/filings/0000950170-25-105857.md) | [3.89](/filings/0001193125-25-272385.md) | not reported | [4.87](/filings/0001193125-26-211992.md) | [5.49](/filings/0001193125-26-340278.md) | [5.92](/filings/0001193125-25-272385.md) | not reported | [5.71](/filings/0001193125-26-211992.md) | [6.01](/filings/0001193125-26-340278.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Operating income: us-gaap:OperatingIncomeLoss - Interest expense: us-gaap:InterestExpense - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [0.1](/filings/0000950170-24-124103.md) | [0.1](/filings/0001193125-26-071676.md) | [0.1](/filings/0000950170-25-067010.md) | [0.1](/filings/0000950170-25-105857.md) | [0.1](/filings/0001193125-25-272385.md) | [0.1](/filings/0001193125-26-071676.md) | [0.1](/filings/0001193125-26-211992.md) | [0.1](/filings/0001193125-26-340278.md) | [0.1](/filings/0001193125-25-272385.md) | [0.1](/filings/0001193125-26-340278.md) | [0.1](/filings/0001193125-26-211992.md) | [0.1](/filings/0001193125-26-340278.md) | | Current assets | $bn | [2.8](/filings/0000950170-23-061147.md) | [2.8](/filings/0000950170-25-027785.md) | [2.9](/filings/0000950170-24-055683.md) | [2.7](/filings/0000950170-24-094006.md) | [2.8](/filings/0000950170-24-124103.md) | [2.8](/filings/0001193125-26-071676.md) | [3.1](/filings/0000950170-25-067010.md) | [3.0](/filings/0000950170-25-105857.md) | [3.3](/filings/0001193125-25-272385.md) | [3.4](/filings/0001193125-26-340278.md) | [3.5](/filings/0001193125-26-211992.md) | [3.7](/filings/0001193125-26-340278.md) | | Total assets | $bn | [13.9](/filings/0000950170-24-124103.md) | [14.0](/filings/0000950170-25-027785.md) | [14.0](/filings/0000950170-24-055683.md) | [14.1](/filings/0000950170-24-094006.md) | [14.4](/filings/0000950170-24-124103.md) | [14.5](/filings/0001193125-26-071676.md) | [14.9](/filings/0000950170-25-067010.md) | [15.0](/filings/0000950170-25-105857.md) | [15.3](/filings/0001193125-25-272385.md) | [15.5](/filings/0001193125-26-340278.md) | [15.7](/filings/0001193125-26-211992.md) | [15.9](/filings/0001193125-26-340278.md) | | Current liabilities | $bn | [2.0](/filings/0000950170-23-061147.md) | [2.0](/filings/0000950170-25-027785.md) | [2.1](/filings/0000950170-24-055683.md) | [2.1](/filings/0000950170-24-094006.md) | [2.0](/filings/0000950170-24-124103.md) | [2.2](/filings/0001193125-26-071676.md) | [2.3](/filings/0000950170-25-067010.md) | [2.3](/filings/0000950170-25-105857.md) | [3.2](/filings/0001193125-25-272385.md) | [3.2](/filings/0001193125-26-340278.md) | [3.2](/filings/0001193125-26-211992.md) | [3.3](/filings/0001193125-26-340278.md) | | Long-term debt | $bn | [4.8](/filings/0000950170-23-061147.md) | [4.8](/filings/0000950170-25-027785.md) | [4.7](/filings/0000950170-24-055683.md) | [4.4](/filings/0000950170-24-094006.md) | [4.6](/filings/0000950170-24-124103.md) | [4.5](/filings/0001193125-26-071676.md) | [4.6](/filings/0000950170-25-067010.md) | [4.5](/filings/0000950170-25-105857.md) | [4.0](/filings/0001193125-25-272385.md) | [4.0](/filings/0001193125-26-340278.md) | [4.0](/filings/0001193125-26-211992.md) | [4.1](/filings/0001193125-26-340278.md) | | Current portion of debt | $bn | [0.1](/filings/0000950170-23-061147.md) | [0.1](/filings/0000950170-25-027785.md) | [0.1](/filings/0000950170-24-055683.md) | [0.1](/filings/0000950170-24-094006.md) | [0.0](/filings/0000950170-24-124103.md) | [0.0](/filings/0001193125-26-071676.md) | [0.0](/filings/0000950170-25-067010.md) | [0.0](/filings/0000950170-25-105857.md) | [0.7](/filings/0001193125-25-272385.md) | [0.7](/filings/0001193125-26-340278.md) | [0.8](/filings/0001193125-26-211992.md) | [0.8](/filings/0001193125-26-340278.md) | | Shareholders' equity | $bn | [6.1](/filings/0000950170-23-061147.md) | [6.1](/filings/0000950170-25-027785.md) | [6.3](/filings/0000950170-24-055683.md) | [6.5](/filings/0000950170-24-094006.md) | [6.6](/filings/0000950170-24-124103.md) | [6.7](/filings/0001193125-26-071676.md) | [6.8](/filings/0000950170-25-067010.md) | [7.0](/filings/0000950170-25-105857.md) | [7.2](/filings/0001193125-25-272385.md) | [7.3](/filings/0001193125-26-340278.md) | [7.5](/filings/0001193125-26-211992.md) | [7.5](/filings/0001193125-26-340278.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Long-term debt: us-gaap:LongTermDebtNoncurrent - Current portion of debt: us-gaap:LongTermDebtCurrent - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [162 d](/filings/0000950170-24-124103.md) | [452 d](/filings/0001193125-26-071676.md) | [396](/filings/0000950170-25-067010.md) | [679 d](/filings/0000950170-25-105857.md) | [333 d](/filings/0001193125-25-272385.md) | [658 d](/filings/0001193125-26-071676.md) | [360](/filings/0001193125-26-211992.md) | [549 d](/filings/0001193125-26-340278.md) | [381 d](/filings/0001193125-25-272385.md) | [575 d](/filings/0001193125-26-071676.md) | [402](/filings/0001193125-26-211992.md) | [443 d](/filings/0001193125-26-340278.md) | | Capital expenditure | $m | [200 d](/filings/0000950170-24-124103.md) | [206 d](/filings/0001193125-26-071676.md) | [209](/filings/0000950170-25-067010.md) | [241 d](/filings/0000950170-25-105857.md) | [248 d](/filings/0001193125-25-272385.md) | [246 d](/filings/0001193125-26-071676.md) | [239](/filings/0001193125-26-211992.md) | [266 d](/filings/0001193125-26-340278.md) | [229 d](/filings/0001193125-25-272385.md) | [281 d](/filings/0001193125-26-071676.md) | [217](/filings/0001193125-26-211992.md) | [228 d](/filings/0001193125-26-340278.md) | | Dividends paid | $m | [13.7 d](/filings/0000950170-24-124103.md) | [13.5 d](/filings/0001193125-26-071676.md) | [13.6](/filings/0000950170-25-067010.md) | [13.4 d](/filings/0000950170-25-105857.md) | [13.3 d](/filings/0001193125-25-272385.md) | [13.0 d](/filings/0001193125-26-071676.md) | [13.5](/filings/0001193125-26-211992.md) | [12.9 d](/filings/0001193125-26-340278.md) | [12.5 d](/filings/0001193125-25-272385.md) | [12.4 d](/filings/0001193125-26-071676.md) | [13.0](/filings/0001193125-26-211992.md) | [11.8 d](/filings/0001193125-26-340278.md) | | Share repurchases | $m | [176 d](/filings/0000950170-24-124103.md) | [162 d](/filings/0001193125-26-071676.md) | [142](/filings/0000950170-25-067010.md) | [95.9 d](/filings/0000950170-25-105857.md) | [183 d](/filings/0001193125-25-272385.md) | [250 d](/filings/0001193125-26-071676.md) | [223](/filings/0001193125-26-211992.md) | [155 d](/filings/0001193125-26-340278.md) | [237 d](/filings/0001193125-25-272385.md) | [352 d](/filings/0001193125-26-071676.md) | [164](/filings/0001193125-26-211992.md) | [321 d](/filings/0001193125-26-340278.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Dividends paid: us-gaap:PaymentsOfDividendsCommonStock - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [73.1](/filings/0000950170-23-061147.md) | [71.5](/filings/0000950170-24-055683.md) | [70.8](/filings/0000950170-24-094006.md) | [69.6](/filings/0000950170-24-124103.md) | [68.5](/filings/0000950170-25-067010.md) | [67.9](/filings/0000950170-25-105857.md) | [68.1](/filings/0001193125-25-272385.md) | [66.0](/filings/0001193125-26-211992.md) | [65.0](/filings/0001193125-26-340278.md) | [63.7](/filings/0001193125-25-272385.md) | [61.7](/filings/0001193125-26-211992.md) | [59.9](/filings/0001193125-26-340278.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:22 ET. No prices; not investment advice.